ESMO

ESMO 2023: Highlights on selpercatinib in RET fusion-positive NSCLC: The LIBRETTO-431 study

By ONA Editor October 23, 2023 No Comments

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

About Author

Related Posts

ASCO 2026: Selpercatinib shows decrease in risk of disease recurrence or death as adjuvant therapy for early-stage RET fusion-positive NSCLC

FDA approves selpercatinib for RET fusion-positive medullary thyroid cancer

FDA approves selpercatinib for RET fusion-positive thyroid cancer

Leave A Reply Cancel Reply